IP Library Granted Patent US 8,975,245
Granted Patent B2
US 8,975,245 · App. 14/069,751 · Granted Mar 10, 2015

Anaesthetic formulation

Inventors: Juliet Marguerite Goodchild (Malvern, AU); Colin Stanley Goodchild (Malvern, AU); Benjamin James Boyd (Warrandyte, AU)
Assignee: Drawbridge Pharmaceuticals Pty Ltd
A61K47/40A61K31/56A61K31/57A61K47/48969B82Y5/00A61K31/573
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,245
App. No.
14/069,751
Granted
Mar 10, 2015
Kind
B2
Abstract

The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.

Claims (9)

1. A formulation comprising a neuroactive steroid anaesthetic formulated with a cyclodextrin, wherein the neuroactive steroid anaesthetic is selected from the group consisting of alphadolone, allopregnanolone, ganaxolone, pregnanolone, acebrochol, hydroxydione, minaxolone and tetrahydroxy corticosterone, or a deuterated, tritiated or labelled derivative or salt thereof, and wherein the cyclodextrin is (7) sulfobutyl ether β-cyclodextrin or an alkyl ether derivative thereof and wherein the molar ratio of neuroactive steroid anaesthetic to cyclodextrin is from 1:1.6 to 1:2.5 except for alphadolone where the complexation ratio is from 1:2 to 1:2.5.

2. The formulation of claim 1 wherein the molar ratio of neuroactive steroid anaesthetic to cyclodextrin is from 1:2 to 1:2.5.

3. The formulation of claim 1 further comprising one or more of an antimicrobial agent, a preservative, a buffer and/or a co-polymer.

4. The formulation of claim 3 wherein the formulation comprises a co-polymer selected from the group consisting of hydroxy propyl methyl cellulose, polyvinyl pyrollidone and carboxymethyl cellulose.

5. The formulation of claim 3 wherein the formulation comprises a buffer, and the pH is from about pH 5.5 to about pH 8.

6. The formulation of claim 1 wherein the formulation comprises a derivative, wherein the derivative is sulfobutyl ether-alkyl ether cyclodextrin.

7. The formulation of claim 6 wherein the cyclodextrin is sulfobutyl ether-ethyl ether, β-cyclodextrin or its sodium salt.

8. A method of treating a human subject comprising administering the formulation of claim 1 to said human subject.

9. A method of inducing anaesthesia or sedation in a human subject, said method comprising administering an effective amount of a formulation of claim 1 to said human subject.

Assignments (3)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Jan 21, 2016
From: DRAWBRIDGE PHARMACEUTICALS PTY LTD
To: DRAWBRIDGE PHARMACEUTICALS PTY LTD
Reel/Frame 037569/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2013
From: GOODCHILD, JULIET MARGUERITE; GOODCHILD, COLIN STANLEY; BOYD, BENJAMIN JAMES
To: GOODCHILD INVESTMENTS PTY LTD; MONASH UNIVERSITY
Reel/Frame 031680/0751 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2013
From: GOODCHILD INVESTMENTS PTY LTD; MONASH UNIVERSITY
To: DRAWBRIDGE PHARMACEUTICALS PTY LTD
Reel/Frame 031682/0395 →
Continuity (4)
Continuation 13574201
Provisional Application 61297249 · Jan 21, 2010
Provisional Application 61385318 · Sep 22, 2010
Related Publication 20140066417A1 · Mar 6, 2014